Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Goodwill & Intangibles (2021 - 2025)

Kiniksa Pharmaceuticals International's Goodwill & Intangibles history spans 5 years, with the latest figure at $20.0 million for Q4 2025.

  • For Q4 2025, Goodwill & Intangibles rose 23.08% year-over-year to $20.0 million; the TTM value through Dec 2025 reached $20.0 million, up 23.08%, while the annual FY2025 figure was $20.0 million, 23.08% up from the prior year.
  • Goodwill & Intangibles reached $20.0 million in Q4 2025 per KNSA's latest filing, up from $15.5 million in the prior quarter.
  • In the past five years, Goodwill & Intangibles ranged from a high of $20.0 million in Q1 2021 to a low of $15.5 million in Q3 2025.
  • Average Goodwill & Intangibles over 5 years is $18.3 million, with a median of $18.9 million recorded in 2021.
  • Peak YoY movement for Goodwill & Intangibles: dropped 18.75% in 2024, then grew 23.08% in 2025.
  • A 5-year view of Goodwill & Intangibles shows it stood at $19.2 million in 2021, then increased by 3.9% to $20.0 million in 2022, then changed by 0.0% to $20.0 million in 2023, then decreased by 18.75% to $16.2 million in 2024, then grew by 23.08% to $20.0 million in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Goodwill & Intangibles are $20.0 million (Q4 2025), $15.5 million (Q3 2025), and $15.8 million (Q2 2025).